AURORA CANNABIS INC (ACB.CA) Fundamental Analysis & Valuation
TSX:ACB • CA05156X8504
4.9 CAD
+0.09 (+1.87%)
Last: Mar 11, 2026, 07:00 PM
This ACB.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
ACB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. ACB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ACB is valued expensive and it does not seem to be growing.
1. ACB.CA Profitability Analysis
1.1 Basic Checks
- In the past year ACB has reported negative net income.
- ACB had a negative operating cash flow in the past year.
- In the past 5 years ACB reported 4 times negative net income.
- In the past 5 years ACB reported 4 times negative operating cash flow.
1.2 Ratios
- The Return On Assets of ACB (-11.45%) is comparable to the rest of the industry.
- With a Return On Equity value of -16.55%, ACB perfoms like the industry average, outperforming 58.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.45% | ||
| ROE | -16.55% | ||
| ROIC | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ACB has a worse Gross Margin (1.35%) than 79.41% of its industry peers.
- In the last couple of years the Gross Margin of ACB has declined.
- The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
2. ACB.CA Health Analysis
2.1 Basic Checks
- ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, ACB has more shares outstanding
- The number of shares outstanding for ACB has been reduced compared to 5 years ago.
- ACB has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -10.44, we must say that ACB is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -10.44, ACB is doing worse than 85.29% of the companies in the same industry.
- ACB has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.06, ACB is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.44 |
ROIC/WACCN/A
WACC8.76%
2.3 Liquidity
- A Current Ratio of 3.06 indicates that ACB has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 3.06, ACB is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
- A Quick Ratio of 1.48 indicates that ACB should not have too much problems paying its short term obligations.
- The Quick ratio of ACB (1.48) is better than 67.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.06 | ||
| Quick Ratio | 1.48 |
3. ACB.CA Growth Analysis
3.1 Past
- ACB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -502.65%.
- Looking at the last year, ACB shows a quite strong growth in Revenue. The Revenue has grown by 16.54% in the last year.
- ACB shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.94% yearly.
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%
3.2 Future
- ACB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.58% yearly.
- The Revenue is expected to grow by 1.97% on average over the next years.
EPS Next Y-2438.15%
EPS Next 2Y27.12%
EPS Next 3Y84.32%
EPS Next 5Y103.58%
Revenue Next Year6.2%
Revenue Next 2Y1.66%
Revenue Next 3Y6.21%
Revenue Next 5Y1.97%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. ACB.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
- Based on the Price/Forward Earnings ratio of 60.64, the valuation of ACB can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of ACB is on the same level as its industry peers.
- When comparing the Price/Forward Earnings ratio of ACB to the average of the S&P500 Index (23.82), we can say ACB is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 60.64 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ACB's earnings are expected to grow with 84.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.12%
EPS Next 3Y84.32%
5. ACB.CA Dividend Analysis
5.1 Amount
- ACB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ACB.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:ACB (3/11/2026, 7:00:00 PM)
4.9
+0.09 (+1.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)06-16 2026-06-16/amc
Inst Owners13.02%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap277.88M
Revenue(TTM)373.12M
Net Income(TTM)-88.74M
Analysts74
Price Target7.17 (46.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-336.98%
Min EPS beat(2)-587.94%
Max EPS beat(2)-86.02%
EPS beat(4)0
Avg EPS beat(4)-329.23%
Min EPS beat(4)-587.94%
Max EPS beat(4)-86.02%
EPS beat(8)2
Avg EPS beat(8)402.7%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.71%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.46%
Revenue beat(4)3
Avg Revenue beat(4)0.88%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)2.46%
Revenue beat(8)6
Avg Revenue beat(8)4.2%
Revenue beat(12)9
Avg Revenue beat(12)4.15%
Revenue beat(16)9
Avg Revenue beat(16)1.91%
PT rev (1m)-14.75%
PT rev (3m)-11.36%
EPS NQ rev (1m)-250.01%
EPS NQ rev (3m)-250.01%
EPS NY rev (1m)-58.56%
EPS NY rev (3m)-58.56%
Revenue NQ rev (1m)-18.09%
Revenue NQ rev (3m)-18.09%
Revenue NY rev (1m)-4.41%
Revenue NY rev (3m)-4.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 60.64 | ||
| P/S | 0.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.52 | ||
| P/tB | 0.58 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.91
EYN/A
EPS(NY)0.08
Fwd EY1.65%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS6.58
BVpS9.46
TBVpS8.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.45% | ||
| ROE | -16.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.35% | ||
| FCFM | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score3
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 87.54% | ||
| Cap/Sales | 5.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.06 | ||
| Quick Ratio | 1.48 | ||
| Altman-Z | -10.44 |
F-Score3
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
EPS Next Y-2438.15%
EPS Next 2Y27.12%
EPS Next 3Y84.32%
EPS Next 5Y103.58%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%
Revenue Next Year6.2%
Revenue Next 2Y1.66%
Revenue Next 3Y6.21%
Revenue Next 5Y1.97%
EBIT growth 1Y-17.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.29%
EBIT Next 3Y38.33%
EBIT Next 5Y21.99%
FCF growth 1Y63.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.56%
OCF growth 3YN/A
OCF growth 5YN/A
AURORA CANNABIS INC / ACB.CA FAQ
Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?
ChartMill assigns a fundamental rating of 2 / 10 to ACB.CA.
What is the valuation status of AURORA CANNABIS INC (ACB.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to AURORA CANNABIS INC (ACB.CA). This can be considered as Overvalued.
What is the profitability of ACB stock?
AURORA CANNABIS INC (ACB.CA) has a profitability rating of 1 / 10.